![Hugues Bienaymé](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hugues Bienaymé
Director Ejecutivo en ORPHELIA Pharma SAS .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Pierre Attali | M | - |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France.
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | 6 años |
Gilles Alberici | M | 67 |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | 9 años |
Julien Alberici | M | - |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | - |
Jean-François Auffret | M | - |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | - |
Maurice Chelli | M | - |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | 7 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Christian Grenier | M | - |
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | 3 años |
Marc Berthon | M | - |
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | - |
Andre Tartar | M | - |
ORPHELIA Pharma SAS
![]() ORPHELIA Pharma SAS Pharmaceuticals: MajorHealth Technology ORPHELIA Pharma SA specializes on biopharmaceutical products improving the health and well being of severely disabled children. The company was founded by Hugues Bienaymé in 2007 and is headquartered in Paris, France. | - |
François Meyer | M | 76 |
Urogene SA
![]() Urogene SA Miscellaneous Commercial ServicesCommercial Services Urogene is a urology-focused biopharmaceutical company engaged in the development of small molecule drugs for the treatment of: Lower Urinary Tract Dysfunctions such as overactive bladder and stress urinary incontinence, Prostate and Bladder Cancers. They have the expertise to set-up and manage preclinical and clinical development plans in these therapeutic areas. Its objective is to provide innovative candidates with clinical proof-of-concept of efficacy and safety. Partnerships with key players in the urology field will be proposed for late-stage clinical development and commercialization. Besipirdine, in-licensed from Aventis, is now reaching that stage. It is a potential novel first-in-class oral treatment for Overactive Bladder (OAB) currently in Phase II development. Development is planned in additional indications including Interstitial Cystitis (IC) and Stress-related Urinary Incontinence (SUI). Besipirdine represents a potential breakthrough and novel blockbuster product in OAB, SUI, mixed incontinence and IC. | - |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Francia | 9 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Hugues Bienaymé
- Red Personal